Erlotinib
About
Therapy type: Targeted therapy
Therapy strategy: EGFR inhibition
Mappings
NCI Thesaurus: Erlotinib (ncit:C65530)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Erlotinib | |
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Erlotinib | |
| FDA (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Erlotinib, Ramucirumab | |
| FDA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Erlotinib, Ramucirumab | |
| EMA (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Bevacizumab, Erlotinib | |
| EMA (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Bevacizumab, Erlotinib | |
| EMA (1) | EGFR oncogenic variants | Non-Small Cell Lung Cancer | Erlotinib, Ramucirumab | |
| EMA (2) HSE (2) | EGFR oncogenic variants | Non-Small Cell Lung Cancer | Erlotinib | |
| HSE (1) | EGFR oncogenic variants | Non-Small Cell Lung Cancer | Bevacizumab, Erlotinib |